Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round on April 18 led by existing investor MPM Capital. I2E, Tetherex board

Read the full 276 word article

How to gain access

Continue reading with a
two-week free trial.